Future trends in the pharmacogenomics of brain disorders and dementia: Influence of APOE and CYP2D6 variants

Pharmaceuticals

Volumn 3, Issue 10, 2010, Pages 3040-3100

  Cacabelos, Ramón ^a,b   Fernández Novoa, Lucía ^a,b   Martínez Bouza, Rocío ^a,b   McKay, Adam ^a,b   Carril, Juan C ^a,b   Lombardi, Valter ^a,b   Corzo, Lola ^a,b   Carrera, Iván ^a,b   Tellado, Iván ^a,b   Nebril, Laura ^a,b   Alcaraz, Margarita ^a,b   Rodríguez, Susana ^a,b   Casas, Ángela ^a,b   Couceiro, Verónica ^a,b   Álvarez, Antón ^a,b  

^a Centro de Investigacion Biomedica EuroEspes   (Spain)

^b CAMILO JOSÉ CELA UNIVERSITY   (Spain)

Author keywords

Alzheimer's disease; APOE; CYPs; Genetics; Pharmacogenomics

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; ARIPIPRAZOLE; BETA SECRETASE INHIBITOR; CHOLINESTERASE INHIBITOR; CITICOLINE; CLOZAPINE; CYTOCHROME P450 2D6; DNA VACCINE; DONEPEZIL; GALANTAMINE; GAMMA SECRETASE INHIBITOR; HALOPERIDOL; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; INDAZOLE DERIVATIVE; MEMANTINE; MICRORNA; NICERGOLINE; NOOTROPIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHENOL DERIVATIVE; PHOSPHOLIPASE A2 INHIBITOR; PIRACETAM; PSYCHOTROPIC AGENT; RISPERIDONE; RIVASTIGMINE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TACRINE; UNINDEXED DRUG;

ALZHEIMER DISEASE; BRAIN DISEASE; CLINICAL TRIAL; COGNITION; DEMENTIA; DEPRESSIVE PSYCHOSIS; DRUG DOSE TITRATION; DRUG EXCRETION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME SUBSTRATE; FUNCTIONAL GENOMICS; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; HEMODYNAMICS; HUMAN; LIPID BLOOD LEVEL; LOW DRUG DOSE; MENTAL DISEASE; NEUROPSYCHIATRY; NONHUMAN; OUTCOMES RESEARCH; PATHOGENESIS; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; REVIEW; STRUCTURAL GENOMICS; TREND STUDY; UNSPECIFIED SIDE EFFECT;

EID: 78650137500     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3103040     Document Type: Review

References (216)

1. Andlin-Sobocki, P.; Jönsson, B.; Wittchen, H.-U.; Olesen, J. Costs of disorders of the brain in Europe. Executive summary. Eur. J. Neurol. 2005, 12 (Suppl. 1), x-xi.
2. Sousa, R.M.; Ferri, C.P.; Acosta, D.; Albanese, E.; Guerra, M.; Huang, Y.; Jacob, K.S.; Jotheeswaran, A.T.; Rodríguez, J.J.; Pichardo, G.R.; et al. Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey. Lancet 2009, 374, 1821-1830.
3. Cacabelos, R. Psychogeriatric research. A conceptual introduction to geriatric neuroscience. Psychogeriatrics 2001, 1, 158-188.
4. Loveman, E.; Green, C.; Kirby, J.; Takeda, A.; Picot, J.; Payne, E.; Clegg, A. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol. Assess. 2006, 10, 1-176.
5. Cacabelos, R.; Álvarez, A.; Lombardi, V.; Fernández-Novoa, L.; Corzo, L.; Pérez, P.; Laredo, M.; Pichel, V.; Hernández, A.; Varela, M.; et al. Pharmacological treatment of Alzheimer disease: From psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today 2000, 36, 415-499.
6. Cacabelos, R. Pharmacogenomic biomarkers in neuropsychiatry: The path to personalized medicine in mental disorders. In The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes; Ritsner, M.S., Eds.; Springer: New York, NY, USA, 2009; Volume 4, pp.3-63.
7. Cacabelos, R. Pharmacogenomics and therapeutic strategies for dementia. Expert Rev. Mol. Diag. 2009, 9, 567-611.
8. Cacabelos, R. Molecular genetics of Alzheimer's disease and aging. Meth. Find. Exper. Clin. Pharmacol. 2005, 27 (Suppl. A), 1-573.
9. Berry, N.; Jobanputra, V.; Pal, H. Molecular genetics of schizophrenia: a critical review. J Psychiatry Neurosci. 2003, 28; 415-429.
10. Kato, T. Molecular genetics of bipolar disorder and depression. Psychiatry Clin. Neurosci. 2007, 61, 3-19.
11. Cacabelos, R. Pharmacogenomics in Alzheimer's disease. Meth. Mol. Biol. 2008, 448, 213-357.
12. Cacabelos, R. Pharmacogenomics for the treatment of dementia. Ann. Med. 2002, 34, 357-79.
13. Cacabelos, R. The application of functional genomics to Alzheimer's disease. Pharmacogenomics 2003, 4, 597-621.
14. Cacabelos, R. Pharmacogenomics and therapeutic prospects in Alzheimer's disease. Exp. Opin. Pharmacother. 2005, 6, 1967-87.
15. Cacabelos, R. Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer's disease. Aging Health 2005, 1, 303-48.
16. Cacabelos, R.; Takeda, M. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer's disease. Drugs of the Future 2006, 31 (Suppl B), 5-146.
17. Roses, A.D. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet. 2004, 5, 645-656.
18. Sharp, A.J.; Cheng, Z.; Eichler, E.E. Structural variation of human genome. Annu. Rev. Genomics Hum. Genet. 2006, 7, 407-442.
19. Crawford, D.C.; Akey, D.T.; Nickerson, D.A. The patterns of natural variation in human genes. Annu. Rev. Genomics Hum. Genet. 2005, 6, 287-312.
20. NCBI. Available online at: http://www.ncbi.nlm.nih.gov/OMIM/, (accessed on 29 September 2010).
21. Alzheimer Research Forum. Available online at: http://www.alzgene.org/, (accessed on 29 September 2010).
22. National Human Genome Research Institute. HUGO Gene Nomenclature Committee. Available online at: http://www.genenames.org (accessed on 29 September 2010).
23. Selkoe, D.J.; Podlisny, M.B. Deciphering the genetic basis of Alzheimer's disease. Annu. Rev. Genomics Hum. Genet. 2002, 3, 67-99.
24. Suh, Y.-H.; Checler, F. Amyloid precursor protein, presenilins, and _-synuclein: Molecular pathogenesis and pharmacological applications in Alzheimer's disease. Phamacol. Rev. 2002, 54, 469-525.
25. Cacabelos, R. Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. Neuropsychiat. Dis. Treat. 2007, 3, 303-333.
26. Strittmatter, W.J.; Saunders, A.M.; Schmechel, D.; Pericak-Vance, M.; Enghild, J.; Salvesen, G.S.; Roses, A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allelein late-onset familial Alzheimer disease. Proc. Nat. Acad. Sci. USA 1993, 90, 1977-1981.
27. Saunders, A.M.; Schmader, K.; Breitner, J.C.; Benson, M.D.; Brown, W.T.; Goldfarb, L.; Goldgaber, D.; Manwaring, M.G.; Szymanski, M.H.; McCown, N.; et al. Apolipoprotein E epsilon-4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 1993, 342, 710-711.
28. Saunders, A.M.; Strittmatter, W.J.; Schamechel, D; St. George-Hyslop, M.D.; Pericak-Vance, M.A.; Joo, S.H.; Rosi, B.L.; Gusella, J.F.; Crapper-MacLachlan, D.R.; Alberts, M.J.; et al. Association of apolipoprotein E allele E4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993, 43, 1467-1472.
29. Corder, E.H.; Saunders, A.M.; Risch, N.J.; Strittmatter, W.J.; Schmechel, D.E.; Gaskell, P.C., Jr.; Rimmler, J.B.; Locke, P.A.; Conneally, P.M.; Schmader, K.E.; et al. Gene dosage of apolipoprotein E type 4 allele and risk of Alzheimer's disease in late onset families. Science 1993, 261, 921-923.
30. Corder, E.H.; Saunders, A.M.; Risch, N.J.; Strittmatter, W.J.; Schmechel, D.E.; Gaskell, P.C., Jr.; Rimmler, J.B.; Locke, P.A.; Conneally, P.M.; Schmader, K.E.; et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genet. 1994, 7, 180-184.
31. Schächter, F.; Faure-Delanef, L.; Guénot, F.; Rouger, H.; Froguel, P.; Lesueur-Ginot, L.; Cohen, D. Genetic association with human longevity at the APOE and ACE loci. Nature Genet. 1994, 6, 29-32.
32. Roses, A.D. Pharmacogenetics and future drug development and delivery. Lancet 2000, 355, 1358-1361.
33. Roses, A.D. Pharmacogenetics and the practice of medicine. Nature 2000, 405, 857-865.
34. Filippini, N.; Ebmeier, K.P.; Macintosh, B.J.; Trachtenberg, A.J.; Frisoni, G.B.; Wilcock, G.K.; Beckmann, C.F.; Smith, S.M.; Matthews, P.M.; Mackay, C.E. Differential effects of the APOE genotype on brain function across the lifespan. Neuroimage 2010, doi:10.1016/j.neuroimage.2010.08.009.
35. Rogaeva, E.; Meng, Y.; Lee, J.H.; Gu, Y.; Kawarai, T.; Zou, F.; Katayama, T.; Baldwin, C.T.; Cheng, R.; Hasegawa, H.; et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer's disease. Nat. Genet. 2007, 39, 168-177.
36. Meng, Y.; Lee, J.H.; Cheng, R.; St George-Hyslop, P.; Mayeux, R.; Farrer, L.A. Association between SORL1 and Alzheimer disease in a genome-wide study. Neuroreport 2007, 18, 1761-1764.
37. Shibata, N.; Ohnuma, T.; Baba, H.; Higashi, S.; Nishioka, K.; Arai, H. Genetic association between SORL1 polymorphisms and Alzheimer's disease in a Japanese population. Dement. Geriatr. Cogn. Disord. 2008, 26, 161-164.
38. Rohe, M.; Synowitz, M.; Glass, R.; Paul, S.M.; Nykjaer, A.; Willnow, T.E. Brain-derived neurotrophic factor reduces amyloidogenic processing through control of SORLA gene expression. J. Neurosci. 2009, 29, 15472-8.
39. Fehér, A.; Juhász, A.; Rimanóczy, A.; Kálmán, J.; Janka, Z. Association between BDNF Val66Met polymorphism and Alzheimer disease, dementia with Lewy bodies, and Pick disease. Alzheimer Dis. Assoc. Disord. 2009, 23, 224-228.
40. Wang, Y.; Rogers, P.M.; Stayrook, K.R.; Su, C.; Varga, G.; Shen, Q.; Nagpal, S.; Burris, T.P. The selective Alzheimer's disease indicator-1 gene (Seladin-1/DHCR24) is a liver X receptor target gene. Mol. Pharmacol. 2008, 74, 1716-1721.
41. Peri, A.; Serio, M. Neuroprotective effects of the Alzheimer's disease gene seladin-1. J. Mol. Endocrinol. 2008, 41, 251-261.
42. Sanders, A.E.; Wang, C.; Katz, M.; Derby, C.A.; Barzilai, N.; Ozelius, L.; Lipton, R.B. Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia. JAMA 2010, 303, 150-158.
43. Schaffer, B.A.; Bertram, L.; Miller, B.L.; Mullin, K.; Weintraub, S.; Johnson, N.; Bigio, E.H.; Mesulam, M.; Wiedau-Pazos, M.; Jackson, G.R.; et al. Association of GSK3B with Alzheimer's disease and frontotemporal dementia. Arch. Neurol. 2008, 65, 1368-1374.
44. Hsu, W.C.; Wang, H.K.; Lee, L.C.; Fung, H.C.; Lin, J.C.; Hsu, H.P.; Wu, Y.R.; Ro, L.S.; Hu, F.J.; Chang, Y.T.; et al. Promoter polymorphisms modulating HSPA5 expression may increase susceptibility to Taiwanese Alzheimer's disease. J. Neural. Transm. 2008, 115, 1537-1543.
45. Chen, Y.; Jia, L.; Wei, C.; Wang, F.; Lv, H.; Jia, J. Association between polymorphisms in the apolipoprotein D gene and sporadic Alzheimer's disease. Brain Res. 2008, 1233, 196-202.
46. Dreses-Werringloer, U.; Lambert, J.C.; Vingtdeux, V.; Zhao, H.; Vais, H.; Siebert, A.; Jain, A.; Koppel, J.; Rovelet-Lecrux, A.; Hannequin, D.; et al. A polymorphism in CALHM1 influences Ca2+ homeostasis, A_ levels, and Alzheimer's disease risk. Cell 2008, 133, 1149-1161.
47. Harold, D.; Abraham, R.; Hollingworth, P.; Sims, R.; Gerrish, A.; Hamshere, M.L.; Pahwa, J.S.; Moskvina, V.; Dowzell, K.; Williams, A.; et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41, 1088-1093.
48. Lambert, J.C.; Heath, S.; Even, G.; Campion, D.; Sleegers, K.; Hiltunen, M.; Combarros, O.; Zelenika, D.; Bullido, M.J.; Tavernier, B.; et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41, 1094-1099.
49. Jun, G.; Naj, A.C.; Beecham, G.W.; Wang, L.S.; Buros, J.; Gallins, P.J.; Buxbaum, J.D.; Ertekin- Taner, N.; Fallin, M.D.; Friedland, R.; et al. Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes. Arch. Neurol. 2010, doi:10.1001/archneurol.2010.201.
50. Seshadri, S.; Fitzpatrick, A.L.; Ikram, M.A.; DeStefano, A.L.; Gudnason, V.; Boada, M.; Bis, J.C.; Smith, A.V.; Carassquillo, M.M.; Lambert, J.C.; et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010, 303, 1832-1840.
51. Kramer, P.L.; Xu, H.; Woltjer, R.L.; Westaway, S.K.; Clark, D.; Erten-Lyons, D.; Kaye, J.A.; Welsh-Bohmer, K.A.; Troncoso, J.C.; Markesbery, W.R.; et al. Alzheimer disease pathology in cognitively healthy elderly: A genome-wide study. Neurobiol. Aging. 2010, doi:10.1016/j.neurobiolaging.2010.01.010.
52. Durakoglugil, M.S.; Chen, Y.; White, C.L.; Kavalali, E.T.; Herz, J. Reelin signaling antagonizes beta-amyloid at the synapse. Proc. Natl. Acad. Sci. U.S.A 2009, 106, 15938-15943.
53. Roses, A.D.; Lutz, M.W.; Amrine-Madsen, H.; Saunders, A.M.; Crenshaw, D.G.; Sundseth, S.S.; Huentelman, M.J.; Welsh-Bohmer, K.A.; Reiman, E.M. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J. 2009, doi: 10.1038/tpj.2009.69.
54. Lutz, M.W.; Crenshaw, D.G.; Saunders, A.M.; Roses, A.D. Genetic variation at a single locus and age of onset for Alzheimer's disease. Alzheimers Demen. 2010, 6, 125-131.
55. Roses, A.D. An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease. Arch. Neurol. 2010, 67, 536-541.
56. Ohe, K.; Mayeda, A. HMGA1a trapping of U1 snRNP at an authentic 5' splice site induces aberrant exon skipping in sporadic Alzheimer's disease. Mol. Cell. Biol. 2010, 30, 2220-2228.
57. Kelley, B.J.; Haidar, W.; Boeve, B.F.; Baker, M.; Shiung, M.; Knopman, D.S.; Rademakers, R.; Hutton, M.; Adamson, J.; Kuntz, K.M.; Dickson, D.W.; Parisi, J.E.; Smith, G.E.; Petersen, R.C. Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin. Arch. Neurol. 2010, 67, 171-177.
58. Yu, C.E.; Bird, T.D.; Bekris, L.M.; Montine, T.J.; Leverenz, J.B.; Steinbart, E.; Galloway, N.M.; Feldman, H.; Woltjer, R.; Miller, C.A.; et al. The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch. Neurol. 2010, 67, 161-170.
59. Smach, M.A.; Charfeddine, B.; Othman, L.B.; Lammouchi, T.; Ltaief, A.; Nafati, S.; Dridi, H.; Bennamou, S.; Limem, K. -1154G/A and -2578C/A polymorphisms of the vascular endothelial growth factor gene in Tunisian Alzheimer patients in relation to beta-amyloid (1-42) and total tau protein. Neurosci. Lett. 2010, 472, 139-142.
60. Jin, Z.; Luxiang, C.; Huadong, Z.; Yanjiang, W.; Zhiqiang, X.; Hongyuan, C.; Lihua, H.; Xu, Y. Endothelin-converting enzyme-1 promoter polymorphisms and susceptibility to sporadic lateonset Alzheimer's disease in a Chinese population. Dis. Markers 2009, 27, 211-215.
61. Xue, S.; Jia, L.; Jia, J. Association between somatostatin gene polymorphisms and sporadic Alzheimer's disease in Chinese population. Neurosci. Lett. 2009, 465, 181-183.
62. Li, K.; Dai, D.; Zhao, B.; Yao, L.; Yao, S.; Wang, B.; Yang, Z. Association between the RAGE G82S polymorphism and Alzheimer's disease. J. Neural. Transm. 2010, 117, 97-104.
63. Takuma, K.; Fang, F.; Zhang, W.; Yan, S.; Fukuzaki, E.; Du, H.; Sosunov, A.; McKhann, G.; Funatsu, Y.; Nakamichi, N.; et al. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc. Natl. Acad. Sci. USA 2009, 106, 20021-20026.
64. Shibata, N.; Ohnuma, T.; Baba, H.; Arai, H. Genetic association analysis between TDP-43 polymorphisms and Alzheimer's disease in a Japanese population. Dement. Geriatr. Cogn. Disord. 2009, 28, 325-329.
65. Listì, F.; Caruso, C.; Lio, D.; Colonna-Romano, G.; Chiappelli, M.; Licastro, F.; Candore, G. Role of cyclooxygenase-2 and 5-lipoxygenase polymorphisms in Alzheimer's disease in a population from northern Italy: implication for pharmacogenomics. J. Alzheimers Dis. 2010, 19, 551-557.
66. Guerini, F.R.; Tinelli, C.; Calabrese, E.; Agliardi, C.; Zanzottera, M.; de Silvestri, A.; Franceschi, M.; Grimaldi, L.M.; Nemni, R.; Clerici, M. HLA-A*01 is associated with late onset of Alzheimer's disease in Italian patients. Int. J. Immunopathol. Pharmaco. 2009, 22, 991-999.
67. Vural, P.; Degirmencioglu, S.; Parildar-Karpuzoglu, H.; Dogru-Abbasoglu, S.; Hanagasi, H.A.; Karadag, B.; Gürvit, H.; Emre, M.; Uysal, M. The combinations of TNFalpha-308 and IL-6 -174 or IL-10 -1082 genes polymorphisms suggest an association with susceptibility to sporadic lateonset Alzheimer's disease. Acta Neurol. Scand. 2009, 120, 396-401.
68. Capurso, C.; Solfrizzi, V.; Colacicco, A.M.; D'Introno, A.; Frisardi, V.; Imbimbo, B.P.; Lorusso, M.; Vendemiale, G.; Denitto, M.; Santamato, A.; et al. Interleukin 6-174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34, 177-182.
69. Yu, J.T.; Song, J.H.; Wang, N.D.; Wu, Z.C.; Zhang, Q.; Zhang, N.; Zhang, W.; Xuan, S.Y.; Tan, L. Implication of IL-33 gene polymorphism in Chinese patients with Alzheimer's disease. Neurobiol. Aging 2010, doi:10.1016/j.neurobiolaging.2010.07.003
70. Butler, H.T.; Warden, D.R.; Hogervorst, E.; Ragoussis, J.; Smith, A.D.; Lehmann, D.J. Association of the aromatase gene with Alzheimer's disease in women. Neurosci. Lett. 2010, 468, 202-206.
71. Vepsäläinen, S.; Helisalmi, S.; Mannermaa, A.; Pirttilä, T.; Soininen, H.; Hiltunen, M. Combined risk effects of IDE and NEP gene variants on Alzheimer disease. J. Neurol. Neurosurg. Psychiatry 2009, 80, 1268-1270.
72. Zhong, L.; Dong-hai, Q.; Hong-ying, L.; Qing-feng, L. Analysis of the nicastrin promoter rs10752637 polymorphism and its association with Alzheimer's disease. Eur. J. Neurosci. 2009, 30, 1831-1836.
73. Laumet, G.; Petitprez, V.; Sillaire, A.; Ayral, A.M.; Hansmannel, F.; Chapuis, J.; Hannequin, D.; Pasquier, F.; Scarpini, E.; Galimberti, D.; et al. A study of the association between the ADAM12 and SH3PXD2A (SH3MD1) genes and Alzheimer's disease. Neurosci. Lett. 2010, 468, 1-2.
74. Leduc, V.; Théroux, L.; Dea, D.; Robitaille, Y.; Poirier, J. Involvement of paraoxonase 1 genetic variants in Alzheimer's disease neuropathology. Eur. J. Neurosci. 2009, 30, 1823-1830.
75. Liu, H.P.; Lin, W.Y.; Liu, S.H.; Wang, W.F.; Tsai, C.H.; Wu, B.T.; Wang, C.K.; Tsai, F.J. Genetic variation in N-methyl-D-aspartate receptor subunit NR3A but not NR3B influences susceptibility to Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2009, 28, 521-527.
76. di Maria, E.; Bonvicini, C.; Bonomini, C.; Alberici, A.; Zanetti, O.; Gennarelli, M. Genetic variation in the G720/G30 gene locus (DAOA) influences the occurrence of psychotic symptoms in patients with Alzheimer's disease. J. Alzheimers Dis. 2009, 18, 953-960.
77. Martínez, M.F.; Martín, X.E.; Alcelay, L.G.; Flores, J.C.; Valiente, J.M.; Juanbeltz, B.I.; Beldarraín, M.A.; López, J.M.; Gonzalez-Fernández, M.C.; Salazar, A.M.; et al. The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers. BMC Neurosc. 2009, 10, 125.
78. Maruszak, A.; Safranow, K.; Gustaw, K.; Kijanowska-Haładyna, B.; Jakubowska, K.; Olszewska, M.; Styczynska, M.; Berdynski, M.; Tysarowski, A.; Chlubek, D.; et al. PIN1 gene variants in Alzheimer's disease. BMC Med. Genet. 2009, 10, 115.
79. Kellett, K.A.; Hooper, N.M. Prion protein and Alzheimer disease. Prion 2009, 3, 190-194.
80. Lloyd, S.E.; Rossor, M.; Fox, N.; Mead, S.; Collinge, J. HECTD2, a candidate susceptibility gene for Alzheimer's disease on 10q. BMC Med. Genet. 2009, 10, 90.
81. Ahn, K.; Song, J.H.; Kim, D.K.; Park, M.H.; Jo, S.A.; Koh, Y.H. Ubc9 gene polymorphisms and late-onset Alzheimer's disease in the Korean population: a genetic association study. Neurosci. Lett. 2009, 465, 272-275.
82. Persengiev, S.; Kondova, I.; Otting, N.; Koeppen, A.H.; Bontrop, R.E. Genome-wide analysis of miRNA expression reveals a potential role for miR-144 in brain aging and spinocerebellar ataxia pathogenesis. Neurobiol. Aging 2010, doi:10.1016/j.neurobiolaging.2010.03.014.
83. Bettens, K.; Brouwers, N.; van Miegroet, H.; Gil, A.; Engelborghs, S.; de Deyn, P.P.; Vandenberghe, R.; van Broeckhoven, C.; Sleegers, K. Follow-up study of susceptibility Loci for Alzheimer's disease and onset age identified by genome-wide association. J. Alzheimers Dis. 2010, 19, 1169-1175.
84. Donkin, J.J.; Stukas, S.; Hirsch-Reinshagen, V.; Namjoshi, D.; Wilkinson, A.; May, S.; Chan, J.; Fan, J.; Collins, J.; Wellington, C.L. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver-X-receptor agonist GW3965 on object recognition memory and amyloid burden in APP/PS1 mice. J. Biol. Chem. 2010, doi: 10.1074/jbc.M110.108100.
85. Kuerban, B.; Shibata, N.; Komatsu, M.; Ohnuma, T.; Arai, H. Genetic Association between PLTP Gene Polymorphisms and Alzheimer's Disease in a Japanese Population. Dement. Geriatr. Cogn. Disord. 2010, 30, 78-82.
86. Bertram, L.; Tanzi, R.E. Genome-wide association studies in Alzheimer's disease. Hum. Mol. Genet. 2009, 18, 137-145.
87. Lin, M.T.; Simon, D.K.; Ahn, C.H.; Kim, L.M.; Beal, M.F. High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Hum. Mol. Genet. 2002, 11, 133-145.
88. Pinho, C.M.; Björk, B.F.; Alikhani, N.; Bäckman, H.G.; Eneqvist, T.; Fratiglioni, L.; Glaser, E.; Graff, C. Genetic and biochemical studies of SNPs of the mitochondrial A beta-degrading protease, hPreP. Neurosci. Lett. 2010, 469, 204-208.
89. Vitali, M.; Venturelli, E.; Galimberti, D.; Benerini Gatta, L.; Scarpini, E.; Finazzi, D. Analysis of the genes coding for subunit 10 and 15 of cytochrome c oxidase in Alzheimer's disease. J. Neural. Transm. 2009, 116, 1635-1641.
90. Takasaki, S. Mitochondrial haplogroups associated with Japanese Alzheimer's patients. J. Bioenerg. Biomembr. 2009, 41, 407-410.
91. Santoro, A.; Balbi, V.; Balducci, E.; Pirazzini, C.; Rosini, F.; Tavano, F.; Achilli, A.; Siviero, P.; Minicuci, N.; Bellavista, E.; et al. Evidence for sub-haplogroup h5 of mitochondrial DNA as a risk factor for late onset Alzheimer's disease. PLoS One 2010, 5, e12037.
92. Zhang, M.; Poplawski, M.; Yen, K.; Cheng, H.; Bloss, E.; Zhu, X; Patel, H.; Mobbs, C.V. Role of CBP and SATB-1 in aging, dietary restriction, and insulin-like signaling. PLoS Biol. 2009, 7, e1000245.
93. Lukens, J.N.; van Deerlin, V.; Clark, C.M.; Xie, S.X.; Johnson, F.B. Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer's disease. Alzheimers Dement. 2009, 5, 463-469.
94. Zekry, D.; Herrmann, F.R.; Irminger-Finger, I.; Graf, C.; Genet, C.; Vitale, A.M.; Michel, J.P.; Gold, G.; Krause, K.H. Telomere length and ApoE polymorphism in mild cognitive impairment, degenerative and vascular dementia. J. Neurol. Sci. 2010, doi:10.1016/j.jns.2010.07.019.
95. Anderson, C.N.G.; Grant, S.G.N. High throughput protein expression screening in the nervous system-needs and limitations. J. Physiol. 2006, 575.2, 367-372.
96. Xu, X.; Zhan, M; Duan, W.; Prabhu, V.; Brenneman, R.; Wood, W.; Firman, J.; Li, H.; Zhang, P.; Ibe, C.; et al. Gene expression atlas of the mouse central nervous system: impact and interactions of age, energy intake and gender. Genome Biol. 2007, 8, 234.
97. Mastrangelo, M.A.; Bowers, W.J. Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neurosci. 2008, 9, 81.
98. Rodríguez, J.J.; Jones, V.C.; Tabuchi, M.; Allan, S.M.; Knight, E.M.; LaFerla, F.M.; Oddo, S.; Verkhratsky, A. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS One 2008, 3, e2935.
99. Cacabelos, R. Pharmacogenomics and therapeutic prospect in dementia. Eur Arch Psychiatry Clin. Neurosci. 2008, 258 (Suppl. 1), 28-47.
100. Cacabelos, R. Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease. Mol. Diag. Ther. 2007, 11, 385-405.
101. Cacabelos, R.; Llovo, R.; Fraile, C.; Fernández-Novoa, L. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. Curr. Alzheimer Res. 2007, 4, 479-500.
102. Cacabelos, R. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenicrelated effects of multifactorial treatments on cognition, anxiety, and depression. Meth. Find. Exper. Clin. Pharmacol. 2007, 29 (Suppl. B), 1-91.
103. Cacabelos, R.; Fernández-Novoa, L.; Pichel, V.; Lombardi, V.; Kubota, Y.; Takeda, M. Pharmacogenomic studies with a combination therapy in Alzheimer's disease. In Molecular Neurobiology of Alzheimer Disease and Related Disorders; Takeda M, Tanaka T, Cacabelos R, Eds.; Karger: Basel, Switzerland, 2004; pp.94-107.
104. Cacabelos, R. Pharmacogenomics in Alzheimer's disease. In Pharmacogenomics and Personalized Medicine; Cohen N, Eds.; Humana Press, Totowa, NJ, USA, 2008, pp.317-368.
105. Thomann, P.A.; Roth, A.S.; Dos Santos, V.; Toro, P.; Essig, M.; Schröder, J. Apolipoprotein E polymorphism and brain morphology in mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 2008, 26, 300-305.
106. Sando, S.B.; Melquist, S.; Cannon, A.; Hutton, M.L.; Sletvold, O.; Saltvedt, I.; White, L.R.; Lydersen, S.; Aasly, J.O. APOE_4 lowers age at onset and is a high risk factor for Alzheimer's disease; A case control study from central Norway. BMC Neurology 2008, 8, 9.
107. Thambisetty, M.; Beason-Held, L.; An, Y.; Kraut, M.A.; Resnick, S.M. APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch. Neurol. 2010, 67, 93-98.
108. Cacabelos, R.; Fernández-Novoa, L.; Corzo, L.; Pichel, V.; Lombardi, V.; Kubota, Y. Genomics and phenotypic profiles in dementia: Implications for pharmacological treatment. Meth. Find. Exper. Clin. Pharmacol. 2004, 26, 421-44.
109. Cacabelos, R.; Fernández-Novoa, L.; Lombardi, V.; Corzo, L.; Pichel, V.; Kubota, Y. Cerebrovascular risk factors in Alzheimer's disease: Brain hemodynamics and pharmacogenomic implications. Neurol. Res. 2003, 25, 567-580.
110. Roher, A.E.; Maarouf, C.L.; Sue, L.I.; Hu, Y.; Wilson, J.; Beach, T.G. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Biomarkers 2009, 14, 493-501.
111. Giacobini, E. Cholinesterases in human brain: the effect of cholinesterase inhibitors on Alzheimer's disease and related disorders. In The Brain Cholinergic System in Health and Disease, Giacobini E, Pepeu G, Eds.; Informa Healthcare, Oxon, UK, 2006, pp.235-64.
112. Reisberg, B.; Doody, R.; Stoffler, A.; Schmitt, F.; Ferris, S.; Möbius, H.J. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 2003, 348, 1333-1341.
113. Schenk, D.B.; Seubert, P.; Grundman, M.; Black, R. A_ immunotherapy: lessons learned for potential treatment of Alzheimer's disease. Neurodegener. Dis. 2005, 2, 255-60.
114. Wisniewski, T.; Boutajangout, A. Vaccination as a therapeutic approach to Alzheimer's disease. Mt. Sinai J. Med. 2010, 77, 17-31.
115. de Strooper, B.; Vassar, R.; Golde, T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 2010, 6, 99-107.
116. Shelton, C.C.; Zhu, L.; Chau, D.; Yang, L.; Wang, R.; Djaballah, H.; Zheng, H.; Li, Y.M. Modulation of gamma-secretase specificity using small molecule allosteric inhibitors. Proc. Natl. Acad. Sci. USA 2009, 106, 20228-20233.
117. Lambracht-Washington, D.; Qu, B.X.; Fu, M.; Eagar, T.N.; Stüve, O.; Rosenberg, R.N. DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA 2009, 302, 1796-1802.
118. Lang, F.; Görlach, A. Heterocyclic indazole derivatives as SGK1 inhibitors, WO2008138448. Expert Opin. Ther. Pat. 2010, 20, 129-35.
119. Sala Frigerio, C.; Kukar, T.L.; Fauq, A.; Engel, P.C.; Golde, T.E.; Walsh, D.M. An NSAID-like compound, FT-9, preferentially inhibits gamma-secretase cleavage of the amyloid precursor protein compared to its effect on amyloid precursor-like protein 1. Biochemistry 2009, 48, 10894-10904.
120. Boado, R.J.; Lu, J.Z.; Hui, E.K.; Pardridge, W.M. IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. Biotechnol. Bioeng. 2010, 105, 627-635.
121. Adachi, H.; Katsuno, M.; Waza, M.; Minamiyama, M.; Tanaka, F.; Sobue, G. Heat shock proteins in neurodegenerative diseases: pathogenic roles and therapeutic implications. Int. J. Hyperthermia 2009, 25, 647-654.
122. Kilgore, M.; Miller, C.A.; Fass, D.M.; Hennig, K.M.; Haggarty, S.J.; Sweatt, J.D.; Rumbaugh G. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2010, 35, 870-880.
123. Hamaguchi, T.; Ono, K; Murase, A.; Yamada, M. Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway. Am. J. Pathol. 2009, 175, 2557-2565.
124. Kalinin, S.; Richardson, J.C.; Feinstein, D.L. A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease. Curr. Alzheimer Res. 2009, 6, 431-437.
125. Roshan, R.; Ghosh, T.; Scaria, V.; Pillai, B. MicroRNAs: novel therapeutic targets in neurodegenerative diseases. Drug Discov. Today 2009, 14, 1123-1129.
126. Maxwell, M.M. RNAi applications in therapy development for neurodegenerative disease. Curr. Pharm. Des. 2009, 15, 3977-3991.
127. Verrils N.M. Clinical proteomics: Present and future prospects. Clin. Biochem. Rev. 2006, 27, 99-116.
128. Doshi, J.A.; Shaffer, T.; Briesacher, B.A. National estimates of medication use in nursing homes: Findings from 1997 Medicare Current Beneficiary Survey and the 1996 Medical Expenditure Survey. J. Am. Geriatr. Soc. 2005, 53, 438-443.
129. Percudani, M.; Barbui, C.; Fortino, I.; Petrovich, L. Antidepressant drugs prescribing among elderly subjects: a population-based study. Int. J. Geriat. Psychiat. 2005, 20, 113-118.
130. Fialová, D.; Topinková, E.; Gambassi, G.; Finne-Soveri, H.; Jónsson, P.V.; Carpenter, I.; Schroll, M.; Onder, G.; Sørbye, L.W.; Wagner, C.; et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA 2005, 293, 1348-1358.
131. Simon, S.R.; Chan, K.A.; Soumerai, S.B.; Wagner, A.K.; Andrade, S.E.; Feldstein, A.C.; Lafata, J.E.; Davis, R.L.; Gurwitz, J.H. Potentially inappropriate medication use by elderly persons in U.S. Health Maintenance Organizations, 2000-2001. J. Am. Geriatr. Soc. 2005, 53, 227-232.
132. Weinshilboum, R. Inheritance and drug response. N. Engl. J. Med. 2003, 348, 529-537.
133. Zhou, S.F.; Di, Y.M.; Chan, E.; Du, Y.M.; Chow, V.D.; Xue, C.C.; Lai, X.; Wang, J.C.; Li, C.G.; Tian, M.; Duan, W. Clinical pharmacogenetics and potential application in personalized medicine. Curr. Drug Metab. 2008, 9, 738-784.
134. Malhotra, A.K.; Lencz, T.; Correll, C.U.; Kane, J.M. Genomics and the future of pharmacotherapy in psychiatry. Int. Rev. Psychiatry 2007, 19, 523-530.
135. Nnadi, C.U.; Malhorta, A.K. Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics. Curr. Psychiatry Rep. 2007, 9, 313-318.
136. Foster, A.; Miller, D.; Buckley, P.F. Pharmacogenetics and schizophrenia. Psychiatr. Clin. North Am. 2007, 30, 417-435.
137. Arranz, M.J.; de Leon, J. Pharmacogenetics and pharmacogenomics of schizophrenia: A review of last decade of research. Mol. Psychiatry 2007, 12, 707-747.
138. Mizutani, T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab. Rev. 2003, 35, 99-106.
139. Xie, H.G.; Prasad, H.G.; Kim, R.B.; Stein, C.M. CYP2C9 allelic variants: ethnic ditribution and functional significance. Adv. Drug Deliv. Rev. 2002, 54, 1257-1270.
140. Isaza, C.A.; Henao, J.; López, A.M.; Cacabelos, R. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Meth. Find. Exp. Clin. Pharmacol. 2000, 22, 695-705.
141. Ozawa, S.; Soyama, A.; Saeki, M.; Fukushima-Uesaka, H.; Itoda, M.; Koyano, S.; Sai, K.; Ohno, Y.; Saito, Y.; Sawada, J. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab. Pharmacokin. 2004, 19, 83-95.
142. Xie, H.G.; Kim, R.B.; Wood, A.J.; Stein, C.M. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharm. Toxicol. 2001, 41, 815-50.
143. Madan, A.; Graham, R.A.; Carroll, K.M.; Mudra, D.R.; Burton, L.A.; Krueger, L.A.; Downey, A.D.; Czerwinski, M.; Forster, J.; Ribadeneira, M.D.; et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab. Dispos. 2003, 31, 421-431.
144. Hedlund, E.; Gustafsson, J.A.; Warner, M. Cytochrome P450 in the brain: a review. Curr. Drug Metabol. 2001, 2, 245-263.
145. Funae, Y.; Kishimoto, W.; Cho, T.; Niwa, T.; Hiroi, T. CYP2D in the brain. Drug Metab. Pharmacokin. 2003, 18, 337-349.
146. Scordo, M.G.; Spina, E. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 2002, 3, 201-218.
147. Ingelman-Sundberg, M.; Sim, S.C.; Gomez, A.; Rodríguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 2007, 116, 496-526.
148. Kobylecki, C.J.; Jakobsen, K.D.; Hansen, T.; Jakobsen, I.V.; Rasmussen, H.B.; Werge, T. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology 2009, 59, 222-226.
149. Kang, R.H.; Jung, S.M.; Kim, K.A.; Lee, D.K.; Cho, H.K.; Jung, B.J.; Kim, Y.K.; Kim, S.H.; Han, C.; Lee, M.S.; Park, J.Y. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J. Clin. Psychopharmacol. 2009, 29, 272-277.
150. Yagihashi, T.; Mizuno, M.; Chino, B.; Sato, Y.; Sakuma, K.; Takebayashi, T.; Takao, T.; Kosaki, K. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. Hum. Psychopharmacol. 2009, 24, 301-308.
151. Fleeman, N.; McLeod, C.; Bagust, A.; Beale, S.; Boland, A.; Dundar, Y.; Jorgensen, A.; Payne, K.; Pirmohamed, M.; Pushpakom, S.; et al. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol. Assess. 2010, 14, 1-182.
152. Buchanan, R.W.; Freedman, R.; Javitt, D.C.; Abi-Dargham, A.; Lieberman, J.A. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr. Bull. 2007, 33, 1120-1130.
153. Tamminga, C.A. The neurobiology of cognition in schizophrenia. J. Clin. Psychiatry 2006, 67, e11.
154. Malhotra, A.K.; Murphy, G.M., Jr; Kennedy, J.L. Pharmacogenetics of psychotropic drug response. Am. J. Psychiatry 2004, 161, 780-796.
155. de León, J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol. Res. 2009, 59, 81-89.
156. Need, A.C.; Keefe, R.S.; Ge, D.; Grossman, I.; Dickson, S.; McEvoy, J.P.; Goldstein, D.B. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur. J. Hum. Genet. 2009, 17, 946-957.
157. Ikeda, M.; Tomita, Y.; Mouri, A.; Koga, M.; Okochi, T.; Yoshimura, R.; Yamanouchi, Y.; Kinoshita, Y.; Hashimoto, R.; Williams, H.J.; et al. Identification of Novel Candidate Genes for Treatment Response to Risperidone and Susceptibility for Schizophrenia: Integrated Analysis Among Pharmacogenomics, Mouse Expression, and Genetic Case-Control Association Approaches. Biol. Psychiatry 2010, 67, 263-269.
158. Iwahashi, K.; Murayama, O.; Aoki, J.; Watanabe, M.; Ishigouoka, J. Influence of serotonin (5-HT) 2A-receptor and transporter (5HTT) gene polymorphism upon the effect of olanzapine. Nihon Shinkei Seishin Yakurigaku Zasshi 2009, 29, 141-144.
159. Wei, Z.; Wang, L.; Xuan, J.; Che, R.; Du, J.; Qin, S.; Xing, Y.; Gu, B.; Yang, L.; Li, H.; et al. Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33, 547-551.
160. Chen, S.F.; Shen, Y.C.; Chen, C.H. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33, 470-474.
161. Chen, S.F.; Shen, Y.C.; Chen, C.H. HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Psychopharmacology (Berlin) 2009, 205, 285-292.
162. Park, S.W.; Lee, J.G.; Ha, E.K.; Choi, S.M.; Cho, H.Y.; Seo, M.K.; Kim, Y.H. Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells. Eur. Neuropsychopharmacol. 2009, 19, 356-362.
163. Zuo, L.; Luo, X.; Krystal, J.H.; Cramer, J.; Charney, D.S.; Gelernter, J. The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenet. Genomics 2009, 19, 437-446.
164. Fatemi, S.H.; Reutiman, T.J.; Folsom, T.D. Chronic psychotropic drug treatment causes differential expression of Reelin signaling system in frontal cortex of rats. Schizophr. Res. 2009, 111, 138-152.
165. Guidotti, A.; Dong, E.; Kundakovic, M.; Satta, R.; Grayson, D.R.; Costa, E. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol. Sci. 2009, 30, 55-60.
166. Cashman, J.R.; Zhang, J.; Nelson, M.R.; Braun, A. Analysis of flavin-containing monooxygenase 3 genotype data in populations administered the anti-schizophrenia agent olanzapine. Drug Metab. Lett. 2008, 2, 100-114.
167. Gupta, M.; Bhatnagar, P.; Grover, S.; Kaur, H.; Baghel, R.; Bhasin, Y.; Chauhan, C.; Verma, B.; Manduva, V.; Mukherjee, O.; et al. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 2009, 10, 385-397.
168. Herken, H.; Erdal, M.; Aydin, N.; Sengul, C.; Karadag, F.; Barlas, O.; Akin, F. The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. DNA Cell Biol. 2009, 28, 515-519.
169. Ujike, H.; Nomura, A.; Morita, Y.; Morio, A.; Okahisa, Y.; Kotaka, T.; Kodama, M.; Ishihara, T.; Kuroda, S. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J. Clin. Psychiatry 2008, 69, 1416-1422.
170. Basile, V.S.; Masellis, M.; McIntyre, R.S.; Meltzer, H.Y.; Lieberman, J.A.; Kennedy, J.L. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J. Clin. Psychiatry 2001, 62 (Suppl 23), 45-66.
171. Gunes, A.; Melkersson, K.I.; Scordo, M.G.; Dahl, M.L. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J. Clin. Psychopharmacol. 2009, 29, 65-68.
172. Gregoor, J.G.; van der Weide, J.; Mulder, H.; Cohen, D.; van Megen, H.J.; Egberts, A.C.; Heerdink, E.R. Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. J. Clin. Psychopharmacol. 2009, 29, 21-25.
173. Mulder, H.; Cohen, D.; Scheffer, H.; Gispen-de Wied, C.; Arends, J.; Wilmink, F.W.; Franke, B.; Egberts, A.C. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J. Clin. Psychopharmacol. 2009, 29, 16-20.
174. Kwon, J.S.; Joo, Y.H.; Nam, H.J.; Lim, M.; Cho, E.Y.; Jung, M.H.; Choi, J.S.; Kim, B.; Kang, D.H.; Oh, S.; et al. Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Arch. Gen. Psychiatry 2009, 66, 1233-1241.
175. Volpi, S.; Potkin, S.G.; Malhotra, A.K.; Licamele, L.; Lavedan, C. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J. Clin. Psychiatry 2009, 70, 801-809.
176. Choi, K.H.; Higgs, B.W.; Weis, S.; Song, J.; Llenos, I.C.; Dulay, J.R.; Yolken, R.H.; Webster, M.J. Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects. BMC Psychiatry 2009, 9, 57.
177. Chana, G.; Lucero, G.; Salaria, S.; Lozach, J.; Du, P.; Woelk, C.; Everall, I. Upregulation of NRG-1 and VAMP-1 in human brain aggregates exposed to clozapine. Schizophr. Res. 2009, 113, 273-276.
178. Ji, B.; La, Y.; Gao, L.; Zhu, H.; Tian, N.; Zhang, M.; Yang, Y.; Zhao, X.; Tang, R.; Ma, G.; et al. A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications. J. Proteome Res. 2009, 8, 3633-3641.
179. Ma, D.; Chan, M.K.; Lockstone, H.E.; Pietsch, S.R.; Jones, D.N.; Cilia, J.; Hill, M.D.; Robbins, M.J.; Benzel, I.M.; Umrania, Y.; et al. Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. J. Proteome Res. 2009, 8, 3284-3297.
180. Dell'Aversano, C.; Tomasetti, C.; Iasevoli, F.; de Bartolomeis, A. Antipsychotic and antidepressant co-treatment: effects on transcripts of inducible postsynaptic density genes possibly implicated in behavioural disorders. Brain Res. Bull. 2009, 79, 123-129.
181. Cacabelos, R., Ed.; World Guide for Drug Use and Pharmacogenomics; EuroEspes Publishing: Coruña, Spain, 2010; In Press.
182. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Available online at: http://www.cypalleles.ki.se (accessed on 29 September 2010).
183. PharmGKB. Available online at: http://www.pharmgkb.org (accessed on 29 September 2010).
184. Sachse, C.; Brockmoller, J.; Bauer, S.; Roots, I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 1997, 60, 284-295.
185. Weinshilboum, R.M.; Wang, L. Pharmacogenetics and pharmacogenomics: Development, science, and translation. Annu. Rev. Genomics Hum. Genet. 2006, 7, 223-245.
186. Pilotto, A.; Franceschi, M.; D'Onofrio, G.; Bizzarro, A.; Mangialasche, F.; Cascavilla, L.; Paris, F.; Matera, M.G.; Pilotto, A.; Daniele, A.; et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology 2009, 73, 761-767.
187. Lamba, J.K.; Lin, Y.S.; Schuetz, E.G.; Thummel, K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 2002, 54, 1271-1294.
188. Mannens, G.S.; Snel, C.A.; Hendrickx, J.; Verhaeghe, T.; Le Jeune, L.; Bode, W.; van Beijsterveldt, L.; Lavrijsen, K.; Leempoels, J.; van Osselaer, N.; et al. The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab. Dispos. 2002, 30, 553-563.
189. Egger, S.S.; Bachmann, A.; Hubmann, N.; Schlienger, R.G.; Krähenbühl, S. Prevalence of potentially inappropriate medication use in elderly patients. Comparison between general medicine and geriatric wards. Drugs Aging 2006, 23, 823-837.
190. Roses, A.D. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety. Neuropsychopharmacology 2009, 34, 6-17.
191. Roses, A.D.; Saunders, A.M.; Huang, Y.; Strum, J.; Weisgraber, K.H.; Mahley, R.W. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenic hypothesis (Alzheimer's disease). Pharmacogenomics J. 2007, 7, 10-28.
192. Risner, M.E.; Saunders, A.M.; Altman, J.F.; Ormandy, G.C.; Craft, S.; Foley, I.M.; Zvartau- Hind, M.E.; Hosford, D.A.; Roses, A.D.; Rosiglitazone in Alzheimer's Disease Study Group. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006, 6, 246-254.
193. Lombardi, V.R.M.; Cacabelos, R. E-SAR-94010: a marine fish extract obtained by advanced biotechnological methods. Drugs Future 1999, 24, 167-176.
194. Cacabelos, R.; Vallejo, A.I.; Lombardi, V.; Fernández-Novoa, L.; Pichel, V. E-SAR-94010 (LipoEsar®): A pleiotropic lipoprotein compound with powerful anti-atheromatous and lipid lowering effects. CNS Drug Rev. 2004, 10, 200-201.
195. Cacabelos, R. Pharmacogenomics and Nutraceuticals. Scientific Progress and Pharmaceutical Development; Ebiotec Foundation: Coruña, Spain, 2004.
196. Philips, K.A.; van Bebber, S.L. Measuring the value of pharmacogenomics. Nat. Rev. Drug Discovery 2005, 4, 500-509.
197. Veenstra, D.L.; Higashi, M.K. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci. 2000, 2, 80-90.
198. Sink, K.M.; Holden, K.F.; Yaffe, K. Pharmacological treatment of neuropsychiatric symptoms of dementia. A review of the evidence. JAMA 2005, 293, 596-608.
199. van Steen, K.; McQueen, M.B.; Herbert, A; Raby, B.; Lyon, H.; Demeo, D.L.; Murphy, A.; Su, J.; Datta, S.; Rosenow, C.; et al. Genomic screening and replication using the same data set in family-based association testing. Nat. Genet. 2005, 37, 683-691.
200. Eichelbaum, M.; Ingelman-Sundberg, M.; Evans, W.E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 2006, 57, 119-137.
201. Sowell, R.A.; Owen, J.B.; Butterfield, D.A. Proteomics in animal models of Alzheimer's and Parkinson's disease. Ageing Res. Rev. 2009, 8, 1-17.
202. Khachaturian, Z.S.; Petersen, R.C.; Gauthier, S; Buckholtz, N.; Corey-Bloom, J.P.; Evans, B.; Fillit, H.; Foster, N.; Greenberg, B.; Grundman, M.; et al. A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium. Alzheimers Dement. 2008, 4, 156-163.
203. Cacabelos, R. Role of nutrition in the prevention of Alzheimer's disease. Aging Health 2005, 1, 359-362.
204. Need, A.C.; Motulsky, A.G.; Goldstein, D.B. Priorities and standards in pharmacogenetic research. Nat. Genet. 2005, 37, 671-681.
205. Johnson, A.D.; Wang, S.; Sadee, W. Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics. Pharmacol. Ther. 2005, 106, 19-38.
206. Ishikawa, T.; Onishi, Y.; Hirano, H.; Oosumi, K.; Nagakura, M.; Tarui, S. Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). Biol. Pharm. Bull. 2004, 27, 939-948.
207. Nishimura, M.; Naito, S. Tissue-specific mRNA expression profiles of human solute carrier transporter superfamilies. Drug Metab. Pharmacokin. 2008, 23, 22-44.
208. Wilcock, D.M.; Colton, C.A. Anti-Aß immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J. Alzheimer Dis. 2008, 15, 555-569.
209. Agrawal, N.; Dasaradhi, P.V.; Mohammed, A.; Malhotra, P.; Bhatnagar, R.K.; Mukherjee, S.K. RNA interference: biology, mechanism, and applications. Microbiol. Mol. Biol. Rev. 2003, 67, 657-685.
210. Spänkuch, B.; Strebhardt, K. RNA interference-based gene silencing in mice: the development of a novel therapeutical strategy. Curr. Pharm. Des. 2005, 11, 3405-3419.
211. Leung, R.K.; Whittaker, P.A. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol. Ther. 2005, 107, 222-239.
212. Ying, S.Y.; Lin, S.L. Intron-mediated RNA interference and microRNA biogenesis. Methods Mol. Biol. 2009, 487, 387-413.
213. González-Alegre, P. Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. Pharmacol. Ther. 2007, 114, 34-55.
214. Aagaard, L.; Rossi, J.J. RNA therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev. 2007, 59, 75-86.
215. Hébert, S.S.; Horré, K.; Nicolaï, L.; Bergmans, B.; Papadopoulou, A.S.; Delacourte, A.; de Strooper, B. MicroRNA regulation of Alzheimer's amyloid precursor protein expression. Neurobiol. Dis. 2009, 33, 422-428.
216. Feng, Z.; Zhao, G.; Lei, Y. Neural stem cells and Alzheimer's disease: challenges and hope. Am. J. Alzheimers Dis. Other Demen. 2009, 24, 52-57.